Last reviewed · How we verify
Antithrombotic agents — Competitive Intelligence Brief
phase 2
Antithrombotic agents
Platelet aggregation inhibitors (e.g. P2Y12 receptor, Factor Xa)
Cardiovascular
Small molecule
Live · refreshed every 30 min
Target snapshot
Antithrombotic agents (Antithrombotic agents) — Bayer. Antithrombotic agents work by inhibiting platelet aggregation and preventing blood clots.
Comparator set (1 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Antithrombotic agents TARGET | Antithrombotic agents | Bayer | phase 2 | Antithrombotic agents | Platelet aggregation inhibitors (e.g. P2Y12 receptor, Factor Xa) | |
| Conventional antithrombotic strategy | Conventional antithrombotic strategy | Duk-Woo Park, MD | marketed | Antithrombotic agents (antiplatelet and/or anticoagulant) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Antithrombotic agents class)
- Bayer · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Antithrombotic agents CI watch — RSS
- Antithrombotic agents CI watch — Atom
- Antithrombotic agents CI watch — JSON
- Antithrombotic agents alone — RSS
- Whole Antithrombotic agents class — RSS
Cite this brief
Drug Landscape (2026). Antithrombotic agents — Competitive Intelligence Brief. https://druglandscape.com/ci/antithrombotic-agents. Accessed 2026-05-15.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab